Baxter’s HyQvia Rises Above FDA’s Theoretical Long-Term Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency officials say long-term immunogenicity issues could manifest among patients taking proposed primary immunodeficiency disorder treatment, but advisory committee concludes risk can be managed.